JP7295038B2 - 小児患者のための生物薬剤組成物及び方法 - Google Patents

小児患者のための生物薬剤組成物及び方法 Download PDF

Info

Publication number
JP7295038B2
JP7295038B2 JP2019566881A JP2019566881A JP7295038B2 JP 7295038 B2 JP7295038 B2 JP 7295038B2 JP 2019566881 A JP2019566881 A JP 2019566881A JP 2019566881 A JP2019566881 A JP 2019566881A JP 7295038 B2 JP7295038 B2 JP 7295038B2
Authority
JP
Japan
Prior art keywords
asthma
antibody
eosinophilic
severe
pediatric subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019566881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522524A (ja
JP2020522524A5 (https=
Inventor
アズミ，ジャハナラ
スタインフェルド，ジョナサン
Original Assignee
グラクソスミスクライン エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン エルエルシー filed Critical グラクソスミスクライン エルエルシー
Publication of JP2020522524A publication Critical patent/JP2020522524A/ja
Publication of JP2020522524A5 publication Critical patent/JP2020522524A5/ja
Priority to JP2023094740A priority Critical patent/JP2023113883A/ja
Application granted granted Critical
Publication of JP7295038B2 publication Critical patent/JP7295038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019566881A 2017-06-06 2018-05-08 小児患者のための生物薬剤組成物及び方法 Active JP7295038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023094740A JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762515641P 2017-06-06 2017-06-06
US62/515,641 2017-06-06
US201862619206P 2018-01-19 2018-01-19
US62/619,206 2018-01-19
PCT/US2018/031518 WO2018226339A1 (en) 2017-06-06 2018-05-08 Biopharmaceutical compositions and methods for pediatric patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023094740A Division JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020522524A JP2020522524A (ja) 2020-07-30
JP2020522524A5 JP2020522524A5 (https=) 2021-07-26
JP7295038B2 true JP7295038B2 (ja) 2023-06-20

Family

ID=64566261

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566881A Active JP7295038B2 (ja) 2017-06-06 2018-05-08 小児患者のための生物薬剤組成物及び方法
JP2023094740A Pending JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023094740A Pending JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Country Status (7)

Country Link
US (2) US11390671B2 (https=)
EP (1) EP3634467A4 (https=)
JP (2) JP7295038B2 (https=)
CN (2) CN119632921A (https=)
BR (1) BR112019025736A2 (https=)
CA (1) CA3064859A1 (https=)
WO (1) WO2018226339A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
KR20210145187A (ko) * 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
ES3057414T3 (en) * 2020-12-22 2026-03-02 Glaxosmithkline Ip Dev Ltd Interleukin 5 binding protein dosage regimen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017033121A1 (en) 2015-08-24 2017-03-02 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
ZA898322B (en) 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5858089A (en) 1997-08-26 1999-01-12 Martinovic; Zoran Corn buttering tool
TR200001117T2 (tr) 1997-10-22 2000-09-21 Ponikau Jens Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler.
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP4597643B2 (ja) 2004-11-24 2010-12-15 富士フイルム株式会社 電子内視鏡
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
JP5035153B2 (ja) 2008-07-14 2012-09-26 市光工業株式会社 車両用灯具
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017033121A1 (en) 2015-08-24 2017-03-02 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Deeks, E. D.，Mepolizumab: A Review in Eosinophilic Asthma，BioDrugs，2016年，Vol.30, No.4，p.361-370，doi:10.1007/s40259-016-0182-5
GSKの「ヌーカラ(R)皮下注用100mg」が厚生労働省より製造販売承認を取得，[online]，グラクソ・スミスクライン株式会社，2016年03月28日，[retrieved on 2022.05.30] ，Retrieved from the Internet: <URL: https://jp.gsk.com/ja-jp/news/press-releases/20160328-nucala-approval-2/>
Ortega, H. G. et al.，Mepolizumab treatment in patients with severe eosinophilic asthma，The New England Journal of Medicine，2015年，Vol.371, No.13，p.1198-1207，doi:10.1056/NEJMoa1403290，[published correction appears in N Engl J Med. 2015 Apr 30;372(18):1777]
大場 延浩 ほか，適応外使用医薬品における小児投与量の現状調査，医療薬学，2005年03月，第31巻, 第3号，p.179-185
日下 隆，適応外使用での小児への用法・用量設計 用法・用量設計の実際，薬局，2015年02月，第66巻, 第2号，p.245-250

Also Published As

Publication number Publication date
JP2020522524A (ja) 2020-07-30
BR112019025736A2 (pt) 2020-06-30
WO2018226339A1 (en) 2018-12-13
US20200157206A1 (en) 2020-05-21
JP2023113883A (ja) 2023-08-16
US11390671B2 (en) 2022-07-19
CA3064859A1 (en) 2018-12-13
CN119632921A (zh) 2025-03-18
US20220380451A1 (en) 2022-12-01
EP3634467A4 (en) 2021-07-28
EP3634467A1 (en) 2020-04-15
US12286472B2 (en) 2025-04-29
CN110913887A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
US12454571B2 (en) Biopharmaceutical compositions
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
US10787509B2 (en) Biopharmaceutical compositions and related methods
BR122024020400A2 (pt) Composição e uso de uma composição
EA046656B1 (ru) Антигенсвязывающие белки, которые связываются с il-5 и используются для лечения заболеваний
HK40080447A (en) Biopharmaceutical compositions
BR122025011033A2 (pt) Composição que compreende um anticorpo anti-il-5, uso terapêutico da mesma, bem como composição farmacêutica que compreende a dita composição
BR122025011067A2 (pt) Composição que compreende um anticorpo anti-il-5 e composição farmacêutica que compreende a dita composição

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230608

R150 Certificate of patent or registration of utility model

Ref document number: 7295038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150